{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:52:03Z","timestamp":1786125123725,"version":"build-2736575974"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEUROSURGERY","NEUROS"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma is the most common primary brain tumor in adults. Standard therapy depends on patient age and performance status but principally involves surgical resection followed by a 6-wk course of radiation therapy given concurrently with temozolomide chemotherapy. Despite such treatment, prognosis remains poor, with a median survival of 16 mo. Challenges in achieving local control, maintaining quality of life, and limiting toxicity plague treatment strategies for this disease. Radiotherapy dose intensification through hypofractionation and stereotactic radiosurgery is a promising strategy that has been explored to meet these challenges. We review the use of hypofractionated radiotherapy and stereotactic radiosurgery for patients with newly diagnosed and recurrent glioblastoma.<\/jats:p>","DOI":"10.1093\/neuros\/nyx115","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T23:10:46Z","timestamp":1495581046000},"page":"24-34","source":"Crossref","is-referenced-by-count":59,"title":["Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma"],"prefix":"10.1227","volume":"82","author":[{"given":"Jennifer L","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Stanford University Cancer Center, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Stanford University Cancer Center, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L","family":"Shaffer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University Cancer Center, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa I","family":"Azoulay","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University Cancer Center, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris C","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University Cancer Center, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Nagpal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, Stanford University Cancer Center, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G","family":"Soltys","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University Cancer Center, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,1]]},"reference":[{"issue":"suppl 5","key":"bib1-20231011","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro Oncol"},{"issue":"3","key":"bib2-20231011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg"},{"issue":"10","key":"bib3-20231011","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"32","key":"bib4-20231011","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"bib5-20231011","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"bib6-20231011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother Oncol"},{"issue":"4","key":"bib7-20231011","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2010.07.021","article-title":"Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme","volume":"81","author":"Chen","year":"2011","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"3","key":"bib8-20231011","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0360-3016(03)01623-7","article-title":"Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme","volume":"58","author":"Floyd","year":"2004","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"2","key":"bib9-20231011","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0167-8140(99)00183-8","article-title":"Hypofractionation in glioblastoma multiforme","volume":"54","author":"Hulshof","year":"2000","journal-title":"Radiother Oncol"},{"issue":"3","key":"bib10-20231011","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/153303460800700311","article-title":"Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme","volume":"7","author":"Lipani","year":"2008","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"bib11-20231011","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijrobp.2009.04.064","article-title":"A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma","volume":"77","author":"Morganti","year":"2010","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"2","key":"bib12-20231011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1022985620284","article-title":"Hypofractionated stereotactic radiotherapy for malignant glioma: a phase I\/II study","volume":"2","author":"Neider","year":"1999","journal-title":"J Radiosurg"},{"issue":"2","key":"bib13-20231011","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijrobp.2008.04.030","article-title":"Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis","volume":"73","author":"Panet-Raymond","year":"2009","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"3","key":"bib14-20231011","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2012.01.035","article-title":"Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme","volume":"84","author":"Reddy","year":"2012","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"2","key":"bib15-20231011","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11060-010-0306-6","article-title":"A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme","volume":"102","author":"Terasaki","year":"2011","journal-title":"J Neurooncol"},{"issue":"18","key":"bib16-20231011","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas","volume":"28","author":"Fogh","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"bib17-20231011","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-011-0744-9","article-title":"Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study","volume":"107","author":"Park","year":"2012","journal-title":"J Neurooncol"},{"issue":"17","key":"bib18-20231011","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1002\/cncr.27372","article-title":"Extended field stereotactic radiosurgery for recurrent glioblastoma","volume":"118","author":"Koga","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"bib19-20231011","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11060-013-1044-3","article-title":"Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas","volume":"112","author":"Hundsberger","year":"2013","journal-title":"J Neurooncol"},{"issue":"1","key":"bib20-20231011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijrobp.2010.09.008","article-title":"Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas","volume":"82","author":"Fields","year":"2012","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"bib21-20231011","author":"Tsien","journal-title":"RTOG 1205"},{"issue":"6","key":"bib22-20231011","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2","article-title":"Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study","volume":"52","author":"Chang","year":"1983","journal-title":"Cancer"},{"issue":"10","key":"bib23-20231011","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/0360-3016(79)90554-6","article-title":"High dose radiation therapy in the treatment of malignant gliomas: final report","volume":"5","author":"Salazar","year":"1979","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"24","key":"bib24-20231011","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/82.24.1918","article-title":"Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma","volume":"82","author":"Loeffler","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"bib25-20231011","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.1992.10.9.1379","article-title":"Radiosurgery as part of the initial management of patients with malignant gliomas","volume":"10","author":"Loeffler","year":"1992","journal-title":"J Clin Oncol"},{"issue":"3","key":"bib26-20231011","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0360-3016(92)90939-F","article-title":"Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage","volume":"30","author":"Mehta","year":"1994","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"suppl 1","key":"bib27-20231011","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000100661","article-title":"Boost Gamma Knife radiosurgery in the treatment of primary glial tumors","volume":"61","author":"Coffey","year":"1993","journal-title":"Stereotact Funct Neurosurg"},{"issue":"1","key":"bib28-20231011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0360-3016(94)00498-A","article-title":"Linac radiosurgery for high-grade gliomas: the University of Florida experience","volume":"32","author":"Buatti","year":"1995","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"2","key":"bib29-20231011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0360-3016(95)00087-F","article-title":"Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas","volume":"33","author":"Gannett","year":"1995","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"3","key":"bib30-20231011","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"2","key":"bib31-20231011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11060-010-0176-y","article-title":"Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme","volume":"98","author":"Anker","year":"2010","journal-title":"J Neurooncol"},{"issue":"3","key":"bib32-20231011","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0360-3016(92)90963-I","article-title":"Radiosurgery for glioblastoma multiforme: the importance of selection criteria","volume":"30","author":"Loeffler","year":"1994","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"5","key":"bib33-20231011","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/01.coc.0000135641.82026.c4","article-title":"Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies?","volume":"27","author":"Lustig","year":"2004","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"bib34-20231011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","article-title":"Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials","volume":"23","author":"Newlands","year":"1997","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"bib35-20231011","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br J Cancer"},{"issue":"22","key":"bib36-20231011","first-page":"5846","article-title":"Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine","volume":"47","author":"Stevens","year":"1987","journal-title":"Cancer Res"},{"issue":"14","key":"bib37-20231011","first-page":"3793","article-title":"Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea","volume":"54","author":"Plowman","year":"1994","journal-title":"Cancer Res"},{"issue":"10","key":"bib38-20231011","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"bib39-20231011","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstrom","year":"2012","journal-title":"Lancet Oncol"},{"issue":"35","key":"bib40-20231011","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International atomic energy agency randomized phase iii study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme","volume":"33","author":"Roa","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"bib41-20231011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0360-3016(96)00455-5","article-title":"Hypofractionated stereotactic radiotherapy in the management of recurrent glioma","volume":"37","author":"Shepherd","year":"1997","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"1","key":"bib42-20231011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0167-8140(93)90040-F","article-title":"Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I\/II study)","volume":"27","author":"Laing","year":"1993","journal-title":"Radiother Oncol"},{"issue":"5","key":"bib43-20231011","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ijrobp.2010.12.074","article-title":"Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas","volume":"82","author":"Cuneo","year":"2012","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"5","key":"bib44-20231011","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ijrobp.2013.04.029","article-title":"Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial","volume":"86","author":"Cabrera","year":"2013","journal-title":"Int J Rad Oncol Biol"},{"issue":"2","key":"bib45-20231011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0360-3016(98)00416-7","article-title":"A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma","volume":"43","author":"Hudes","year":"1999","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"1","key":"bib46-20231011","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","article-title":"Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas","volume":"75","author":"Gutin","year":"2009","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"2","key":"bib47-20231011","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0999-9","article-title":"Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas","volume":"111","author":"Minniti","year":"2013","journal-title":"J Neurooncol"},{"issue":"2","key":"bib48-20231011","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0167-8140(02)00386-9","article-title":"Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas","volume":"67","author":"Baumert","year":"2003","journal-title":"Radiother Oncol"},{"issue":"5","key":"bib49-20231011","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ijrobp.2006.02.042","article-title":"A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023","volume":"65","author":"Cardinale","year":"2006","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"bib50-20231011","author":"Mehta","journal-title":"NRG-BN001"},{"issue":"1","key":"bib51-20231011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-014-1691-z","article-title":"Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma","volume":"122","author":"Ney","year":"2015","journal-title":"J Neurooncol"},{"issue":"suppl; abstr LBA2","key":"bib52-20231011","article-title":"A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677)","volume":"34","author":"Perry","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"bib53-20231011","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/1078-0432.CCR-14-0822","article-title":"Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma","volume":"20","author":"Omuro","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"bib54-20231011","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijrobp.2007.07.2382","article-title":"A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas","volume":"70","author":"Schwer","year":"2008","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"10","key":"bib55-20231011","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"bib56-20231011","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","article-title":"Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status","volume":"27","author":"Brandes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"bib57-20231011","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2005.09.001","article-title":"Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]","volume":"64","author":"Cao","year":"2006","journal-title":"Int J Rad Oncol Biol Phys"}],"container-title":["Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neurosurgery\/article-pdf\/82\/1\/24\/32601498\/nyx115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ovid.com\/00006123-201801000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:50:36Z","timestamp":1786121436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006123-201801000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,10]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1093\/neuros\/nyx115","relation":{},"ISSN":["0148-396X","1524-4040"],"issn-type":[{"value":"0148-396X","type":"print"},{"value":"1524-4040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,10]]}}}